The HES1 Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the NCI-H1975 human lung adenocarcinoma cell line, designed for functional studies of HES1, a basic helix-loop-helix transcriptional repressor central to Notch signaling. This heterogeneous loss-of-function model avoids clonal artifacts while providing robust gene disruption for diverse cell-based assays.
The parental NCI-H1975 cell line originates from a female non-small cell lung cancer patient and harbors EGFR L858R/T790M mutations, conferring resistance to first- and second-generation tyrosine kinase inhibitors. Widely used as a model for EGFR-mutant lung adenocarcinoma, it enables investigation of signaling crosstalk between oncogenic drivers and developmental pathways.
HES1 functions as a primary effector of canonical Notch signaling: upon ligand-induced receptor cleavage, NICD translocates to the nucleus and forms a transcriptional activation complex with RBPJ and MAML proteins, driving HES1 expression. HES1 protein then recruits TLE/Groucho co-repressors to silence downstream targets, including the proneural transcription factors ASCL1 and NEUROG2, the cell cycle inhibitors p21 and p27, and the pro-apoptotic factor PUMA. HES1 also auto-represses its own promoter, maintaining oscillatory expression dynamics. In addition to Notch, HES1 is regulated by STAT3, TGF-??, Wnt ligands, and HIF-1??, allowing integration of diverse signals that control cell differentiation, proliferation, and stem cell maintenance.
In the NCI-H1975 adenocarcinoma background, HES1 knockout provides a physiologically relevant model to investigate how Notch-mediated transcriptional repression contributes to malignant phenotypes, including cancer stem cell self-renewal, EMT, and acquired resistance to EGFR-targeted therapies. The presence of the T790M gatekeeper mutation makes this system particularly valuable for studying therapeutic combinations that pair Notch inhibition with third-generation EGFR inhibitors. This gene-edited cell population thus supports mechanistic studies and drug discovery efforts focused on overcoming TKI resistance in NSCLC.
The polyclonal knockout cell population is suited for a wide array of assays: western blotting and RT-qPCR to confirm HES1 loss and derepression of target genes; MTT and Annexin V assays to measure proliferation and apoptosis; tumorsphere formation and transwell migration/invasion assays to evaluate stemness and metastatic potential; and cell viability-based drug sensitivity profiling against EGFR inhibitors and standard-of-care chemotherapeutics. Transcriptional readouts can be obtained using Notch reporter luciferase constructs or ChIP-qPCR, while RNA-seq permits global expression analysis. These cells therefore enable comprehensive functional genomic, phenotypic, and pharmacologic investigations of HES1 in lung adenocarcinoma. For additional details, please contact Ascent Research.
